Filtered By:
Condition: Stroke
Drug: Metformin

This page shows you your search results in order of relevance. This is page number 19.

Order by Relevance | Date

Total 446 results found since Jan 2013.

Pediatric obesity: Causes, symptoms, prevention and treatment.
Authors: Xu S, Xue Y Abstract Pediatric or childhood obesity is the most prevalent nutritional disorder among children and adolescents worldwide. Approximately 43 million individuals are obese, 21-24% children and adolescents are overweight, and 16-18% of individuals have abdominal obesity. The prevalence of obesity is highest among specific ethnic groups. Obesity increases the risk of heart diseases in children and adults. Childhood obesity predisposes the individual to insulin resistance and type 2 diabetes, hypertension, hyperlipidemia, liver and kidney diseases and causes reproductive dysfunction in adults. Obe...
Source: Experimental and Therapeutic Medicine - February 4, 2016 Category: Journals (General) Tags: Exp Ther Med Source Type: research

Summary: International Kidney Cancer Symposium
Conclusions:  Ideal ischemia time is 20-25 minutes or less improves short and long term renal function.  >25 minutes carried 5 year risk of new onset stage 4 CKD No differences on GFR for cold vs. warm ischemia times Preoperative GFR and the percent of kidney preserved was a better predictor of post op GFR.  No ischemia preserves renal function better than warm. Longer cold ischemia times were equivalent to shorter warm ischemia times. Quality and quantity of the remaining kidney is associated with ultimate renal function. Robotics in RCC Surgery Gennady Bratslavsky, MD The...
Source: Kidney Cancer Association - December 15, 2011 Category: Urology & Nephrology Source Type: news

Comparative Cardiovascular Safety of Glucagon‐Like Peptide‐1 Receptor Agonists versus Other Antidiabetic Drugs in Routine Care: a Cohort Study
ConclusionsThis large study, performing head‐to‐head comparisons of GLP‐1 RA versus other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to rule out large differences in CVD risk and adds further understanding to results from recent clinical trials.
Source: Diabetes, Obesity and Metabolism - March 23, 2016 Category: Endocrinology Authors: Elisabetta Patorno, Brendan M. Everett, Allison B. Goldfine, Robert J. Glynn, Jun Liu, Chandrasekar Gopalakrishnan, Seoyoung C. Kim Tags: Original Article Source Type: research

PodMed: A Medical News Roundup From Johns Hopkins (with audio)
(MedPage Today) -- This week's topics include reducing suicide, CABG plus medicines for some people, stroke risk following a TIA, and metformin first for type 2 diabetes
Source: MedPage Today Primary Care - April 23, 2016 Category: Primary Care Source Type: news

Comparative risk of major cardiovascular events associated with second‐line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalisation and mortality records
ConclusionsThiazolidinedione add‐on treatments to metformin were associated with lower risks for major cardiovascular disease or cardiovascular death compared to sulphonylurea combination with metformin. Lower, but non‐statistically significant, risks were also found with DPP‐4i add‐on therapies.
Source: Diabetes, Obesity and Metabolism - May 12, 2016 Category: Endocrinology Authors: Salwa S Zghebi, Douglas T Steinke, Martin K Rutter, Richard A Emsley, Darren M Ashcroft Tags: ORIGINAL ARTICLE Source Type: research

Comparative Risk for Cardiovascular Diseases of Dipeptidyl Peptidase-4 Inhibitors vs. Sulfonylureas in Combination with Metformin: Results of a Two-Phase Study
The aim was to assess whether the use of additional data from the Disease Management Program (DMP) diabetes mellitus type 2 to minimize the potential for residual confounding will alter the estimated risk of either myocardial infarction, ischemic stroke or heart failure in patients with type 2 diabetes using sulfonylureas compared to dipeptidyl peptidase-4 (DPP-4) inhibitors in addition to metformin based on routine health care data.
Source: Journal of Diabetes and Its Complications - May 18, 2016 Category: Endocrinology Authors: Dirk Enders, Bianca Kollhorst, Susanne Engel, Roland Linder, Frank Verheyen, Iris Pigeot Source Type: research

Cardiovascular Safety of Glucose‐Lowering Agents as Add‐on Medication to Metformin Treatment in Type 2 Diabetes:Report from the Swedish National Diabetes Register (NDR)
Conclusions: This nationwide observational study showed that second‐line treatment with TZD and DPP‐4i as add‐on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
Source: Diabetes, Obesity and Metabolism - May 31, 2016 Category: Endocrinology Authors: Nils Ekström, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Zethelius, Björn Eliasson, Soffia Gudbjörnsdottir Tags: ORIGINAL ARTICLE Source Type: research

Cardiovascular safety of glucose ‐lowering agents as add‐on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register
ConclusionsThis nationwide observational study showed that second‐line treatment with TZD and DPP‐4 inhibitor as add‐on medication to metformin were associated with significantly lower risks of mortality and cardiovascular events compared with SU, whereas basal insulin was associated with a higher risk of mortality.
Source: Diabetes, Obesity and Metabolism - July 18, 2016 Category: Endocrinology Authors: Nils Ekstr öm, Ann‐Marie Svensson, Mervete Miftaraj, Stefan Franzén, Björn Zethelius, Björn Eliasson, Soffia Gudbjörnsdottir Tags: ORIGINAL ARTICLE Source Type: research

Comparative risk of major cardiovascular events associated with second ‐line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records
ConclusionsThiazolidinedione add‐on treatments to metformin were associated with lower risks of major cardiovascular disease or cardiovascular death compared with sulphonylurea add‐on treatment to metformin. Lower, but non‐statistically significant, risks were also found with DPP‐4 inhibitor add‐on therapies.
Source: Diabetes, Obesity and Metabolism - June 29, 2016 Category: Endocrinology Authors: S. S. Zghebi, D. T. Steinke, M. K. Rutter, R. A. Emsley, D. M. Ashcroft Tags: ORIGINAL ARTICLE Source Type: research

Comparative cardiovascular safety of glucagon ‐like peptide‐1 receptor agonists versus other antidiabetic drugs in routine care: a cohort study
ConclusionsThis large study, performing head‐to‐head comparisons of GLP‐1 RAs with other antidiabetic agents in real‐world patients, provides estimates of relative safety precise enough to exclude large differences in CVD risk and adds further understanding to results from recent clinical trials.
Source: Diabetes, Obesity and Metabolism - May 1, 2016 Category: Endocrinology Authors: E. Patorno, B. M. Everett, A. B. Goldfine, R. J. Glynn, J. Liu, C. Gopalakrishnan, S. C. Kim Tags: ORIGINAL ARTICLE Source Type: research

Comparative risk for cardiovascular diseases of dipeptidyl peptidase-4 inhibitors vs. sulfonylureas in combination with metformin: Results of a two-phase study
The aim was to assess whether the use of additional data from the Disease Management Program (DMP) diabetes mellitus type 2 to minimize the potential for residual confounding will alter the estimated risk of either myocardial infarction, ischemic stroke or heart failure in patients with type 2 diabetes using sulfonylureas compared to dipeptidyl peptidase-4 (DPP-4) inhibitors in addition to metformin based on routine health care data.
Source: Journal of Diabetes and Its Complications - May 18, 2016 Category: Endocrinology Authors: Dirk Enders, Bianca Kollhorst, Susanne Engel, Roland Linder, Frank Verheyen, Iris Pigeot Source Type: research

Intensive treatment of type 2 diabetes with microalbuminuria reaps benefits
Patients live longer, and with fewer complications, than those treated conventionally Related items fromOnMedica Metformin lowers cardiac deaths better than other drugs NHS Health Check waste of time and money, says study Diabetes, stroke and heart attack cut life expectancy Send children with suspected diabetes to hospital immediately, GPs urged NHS must hold CCGs accountable for poor diabetes care
Source: OnMedica Latest News - September 1, 2016 Category: UK Health Source Type: news

Cardiovascular events and all-cause mortality with insulin versus glucagon-like peptide-1 analogue in type 2 diabetes
Conclusions In this cohort of obese people with T2DM, intensification of dual oral therapy by adding GLP-1ar analogue is associated with a lower MACE outcome in routine clinical practice, compared with adding insulin therapy as the third glucose-lowering agent.
Source: Heart - September 12, 2016 Category: Cardiology Authors: Anyanwagu, U., Mamza, J., Mehta, R., Donnelly, R., Idris, I. Tags: Drugs: cardiovascular system, Acute coronary syndromes, Epidemiology, Diabetes, Metabolic disorders Healthcare delivery, economics and global health Source Type: research

Drug could cut heart events by 26% in diabetics
Experimental drug could also reduce non-fatal strokes Related items fromOnMedica Stroke can often be avoided, claims study Intensive treatment of type 2 diabetes with microalbuminuria reaps benefits Metformin doesn ’t help HbA1c in teens with type 1 diabetes Statins associated with 46% increased diabetes risk Metformin lowers cardiac deaths better than other drugs
Source: OnMedica Latest News - September 18, 2016 Category: UK Health Source Type: news

Impact of bromocriptine-QR therapy on cardiovascular outcomes in type 2 diabetes mellitus subjects on metformin.
CONCLUSION: These findings suggest that in T2DM subjects on metformin, BQR therapy may represent an effective strategy for reducing CVD risk. PMID: 27687032 [PubMed - as supplied by publisher]
Source: Postgraduate Medicine - October 2, 2016 Category: Internal Medicine Tags: Postgrad Med Source Type: research